Skip to main content

Table 1 Clinical profile and follow-up data of seven patients with hypothalamic-pituitary Langerhans cell histiocytosis

From: Clinicopathological features and BRAFV600E mutations in patients with isolated hypothalamic-pituitary Langerhans cell histiocytosis

No. Age (years)/ Gender The interval between onset of symptoms and diagnosis CDI Sites of involvement Follow-up Therapy
  (months) At presentation Follow-up
1 9 / Female 108 Present PS None Alive, 39 ms RT + HRT
2 47 / Female 1 Present PS PS Alive, 5 ms HRT
3 12 / Female 36 Present PS + H PS + H Alive, 5 ms HRT
4 22 / Male 2 Present PS + P NA NA NA
5 13 / Male 4 Present PS + H None Alive, 41 ms RT + HRT
6 15 / Male 1 Present PS + P PS + P Alive, 2 ms HRT
7 35 / Female 18 Present PS Liver involvement suspected Died, 74 ms RT + Surgery + HRT
  1. PS pituitary stalk, H hypothalamus, P pituitary, NA not available, RT radiotherapy, CDI central diabetes insipidus, HRT hormone replacement therapy